ProEx C immunocytochemistry and high-risk human papillomavirus DNA testing in papanicolaou tests with atypical squamous cell (ASC-US) cytology: Correlation study with histologic biopsy

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 10, 2008, Pages 1648-1652

  Siddiqui, Momin T ^a   Hornaman, Kelly ^a   Cohen, Cynthia ^a   Nassar, Aziza ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); MINICHROMOSOME MAINTENANCE PROTEIN 2; BIOLOGICAL MARKER; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; MCM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; TUMOR ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CELL CYCLE REGULATION; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA; UTERUS BIOPSY; WART VIRUS; ALPHAPAPILLOMAVIRUS; BIOPSY; COMPARATIVE STUDY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX; UTERINE CERVIX TUMOR; VAGINA SMEAR;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; BIOPSY; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CERVIX UTERI; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, VIRAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 54449088432     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407-1427.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1.0. Lyon, France: IARC Press; 2001. IARC Cancer Base; no 5.
3. Stoler MH. Cervical cancer screening in the HPV era: what is the standard of care? In: Programs and abstracts of Pathology Today: American Society for Clinical Pathology 2005 Annual Meeting; October 8-11, 2005; Seattle, Wash. Session SP 20.
4. Kinney W, Sung HY, Kearney KA, Miller M, Sawaya G, Hiatt RA. Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer. Gynecol Oncol. 1998;71:428-430.
5. Kinney WK, Manos MM, Hurley LB, Ransley JE. Where is the high grade cervical neoplasia?: the importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol. 1998;91:973-976.
6. Sawaya GF, Grimes DA. New technologies in cervical cytology screening; a word of caution. Obstet Gynecol. 1999;94:307-310.
7. Nanda K, McCrory DC, Myers ER. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytological abnormalities: a systematic review. Ann Intern Med, 2000;132:737-743.
8. Cox JT, Schiffman M, Solomon D; for the ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003;188:1406-1412.
9. Sherman ME, Solomon D, Schiffman M; for the ASCUS-LSIL Triage Study (ALTS) Group. Qualification of ASCUS: a comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. Am J Clin Pathol. 2001;116:386-394.
10. Davey DD, Woodhouse S, Styer P, Stastny J, Mody D. Atypical epithelial cells and specimen adequacy: current laboratory practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2000;124:203-211.
11. Solomon D, Schiffman M, Tarone R; for the ALTS Study Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
12. Waxman AG. Guidelines for cervical cancer screening: history and scientific rationale. Clin Obstet Gynecol. 2005;48:77-97.
13. Wang SS, Walker H, Schiffman M, Solomon D. Evaluating the risk of cervical precancer with a combination of cytologic, virologic, and visual methods. Cancer Epidemiol Biomarkers Prev. 2005;14(11, pt 1):2665-2668.
14. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46-52.
15. Schiffman M, Khan MJ, Solomon D, et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005;97:147-150.
16. Kelly D, Kincaid E, Fransier Z, Rosenthal DL, Clark DP. Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx C). Cancer. 2006;108:494-500.
17. Malinowski DP. Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. Biotechniques. 2005;38:S17-S23.
18. Murphy N, Ring M, Heffron CCBB, et al. p16INK4a, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol. 2005;58:525-534.
19. Chen Y, Miller C, Mosher R, et al. Identification of cervical cancer biomarkers by cDNA and tissue microarrays. Cancer Res. 2003;63:1927-1935.
20. Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV 16 and HPV 18 infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate biomarkers for cervical cancer diagnosis and therapy. Virology. 2005;331:269-291.
21. Freeman A, Morris LS, Mills AD, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res. 1999;5:2121-2132.
22. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem. 2001;70:369-413.
23. Solomon D, Nayar R, eds. The Bethesda System for Reporting Cervical Cytology. 2nd ed. New York, NY: Springer; 2004.
24. American Cancer Society. Cancer Facts and Figures 2008. Atlanta, Ga: American Cancer Society; 2008.
25. Schiffman M, Solomon D. Findings to date from the ASC-US-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003;127:946-949.
26. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of HPV types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
27. Lörincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med. 2003;127:959-968.
28. Arbyn M, Buntinkx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004;96:280-293.
29. de Cremoux P, Coste J, Sastre-Garau X, et al. Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening: a study by the French Society of Clinical Cytology. Am J Clin Pathol. 2003;120:492-499.
30. Guo M, Hu L, Baliga M, et al. The predictive value of p16INK4a and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2004;122:894-901.
31. Shroyer KR, Homer P, Heinz D, Singh M. Validation of a novel immunocytochemical assay for topoisomerase II-α and minichromosome maintenance protein 2 expression in cervical cytology. Cancer. 2006;108:324-330.